1. Department of Respiratory and Critical Care, 2. Department of Disinfection Supply, 3. Department of Preventive Health, Qinhuangdao First Hospital,Qinhuangdao 066000,China; 4. Beijing Municipal Corps Hospital,Chinese People’s Armed Police Force,Beijing 100027,China
Abstract：Objective To explore the clinical effect of rivaroxaban anticoagulant therapy against chronic obstructive pulmonary disease complicated with pulmonary hypertension.Methods In this study, the clinical data on 163 patients with COPD complicated with pulmonary hypertension admitted to our hospital between January 2016 to January 2018 was collected. Such information as the age, gender, body mass index, 6-minute walk test, NT-proBNP, blood analysis, lung function, arterial blood gas analysis and heart color ultrasound of the patients was collected. The control group was given the routine oxygen therapy as well as anti-inflammatory, phlegm-reducing and antiasthmatic treatment, while the treatment group additionally received rivaroxaban 10mg/day oral anticoagulant therapy.Results of cardiac ultrasound, arterial blood gas analysis and 6-minute walking test were compared between the two groups after 30 days of treatment. The data on pulmonary artery pressure, 6-minute walking distance, arterial oxygen partial pressure and carbon dioxide partial pressure in both groups was statistically analyzed.Results Pulmonary arterial pressure decreased significantly in the experimental group after rivaroxaban anticoagulant treatment compared with the control group[(32.7±3.8) vs(51.2±2.7),(P<0.05)]. The 6-minute walking distance of the experimental group was significantly increased compared with the control group[(467.7±5.4) vs (397.8±4.8),(P<0.05)]. The partial pressure of arterial oxygen in the experimental group was significantly higher than that of the control group[(75.6±3.7) vs (63.7±4.5),(P<0.05)]. Arterial partial pressure of carbon dioxide decreased significantly compared with the control group[(43.6±3.7) vs(49.7±2.9)]. The above indexes in the experimental group were significantly improved compared with the control group, and the difference was statistically significant.Conclusions Rivaroxaban anticoagulant therapy has a good clinical effect on chronic obstructive pulmonary disease complicated with pulmonary hypertension, It can improve the quality of life and prognosis of patients.
Wang C,Xu J Y,Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary healthstudy):a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.
[2]
Marc D, Wim J, Yang L,et al. Chronic obstructive pulmonary disease[J]. Lancet, 2012,379(9823): 1341-1351.
Shi Xiaoshan, Li Hongyun. Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage[J].Exp Ther Med,2013,5(5):1367-1370.
[9]
Erhan U, Emine K T, Llknur C, et al. Impaired hemorheology in exacerbations of COPD[J].Can Respir J,2017,9:1286263.
2021, Vol. 32 
